DUBLIN – Enyo Pharma SAS closed a €22 million (US$24.4 million) series A round to move its lead drug, EYP001, into clinical development in chronic hepatitis B virus (HBV) infection in the coming months.
The Lyon, France-based company is entering a crowded field, but it is taking a highly differentiated approach to HBV therapy. It is tackling latent reservoirs of infection maintained by covalently closed circular DNA (cccDNA), a species that can reside within the nuclei of infected patients' hepatocytes for decades, even if they have recovered from an acute infection. And it is doing so by modulating a host rather than a viral target – the nuclear receptor farnesoid X receptor (FXR), which is highly expressed in the liver. Following activation by bile